---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-114097"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:29:41.966871+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November

## Summary
- Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.
- Cash, cash equivalents and short-term investments $17.2M as of Sep 30, 2024 (vs $19.1M Dec 31, 2023); runway into 2026.
- NXP800 Phase 1b clinical data update expected November 2024; received FDA Orphan Drug Designation for ARID1a-deficient ovarian cancers.
- NXP900 Phase 1a dose escalation: 4 cohorts completed with no DLTs; dose continuing; combo plans in NSCLC.

## SEC filing metadata
- accession: 0001104659-24-114097
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465924114097/0001104659-24-114097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465924114097/tm2427419d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-114097
- JSON: https://secwatch.observer/filing/0001104659-24-114097.json
- Plain text: https://secwatch.observer/filing/0001104659-24-114097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.